On September 11, 2023, a London startup most people had never heard of closed a $3.2 million seed round. The company was called Co:Helm then—an angular, forgettable name that wouldn't survive the year. But the bet Sequoia placed through its Arc program that day was anything but forgettable.
The target? Prior authorization. That bureaucratic gauntlet where insurers decide whether to approve medical procedures before they happen. It's the kind of administrative machinery that makes physicians want to quit and patients want to scream—and according to co-founder Abdel Mahmoud, it's chewing through something approaching a trillion dollars in wasted time and paperwork annually.
Mahmoud, a physician who'd traded his stethoscope for product roles at Google and Meta, teamed up with CTO Zahid Mahmood to build what they believed could be a clinical AI co-pilot capable of handling these authorization decisions end-to-end. The pitch was straightforward, if audacious: automate one of the most human-intensive, error-prone processes in American healthcare.
Sequoia saw something there.
A Bet on Pedigree and Pain Points
Beyond Sequoia's early conviction, the round attracted a clutch of funds and individual backers whose names read like a who's who of AI and early-stage capital. Blue Lion Global, Nebular, Ventures Together, Four Acres Capital, and Anamcara all participated. On the angel side: Mustafa Suleyman, the DeepMind and Inflection AI co-founder, alongside Omid Ashtari, Darian Shirazi, and Mandeep Singh.
It was the kind of investor roster that suggests more than polite interest. Mahmoud's academic background—a medical degree and a master's in computer science from University College London—gave him credibility with clinicians. His product experience at two of tech's biggest platforms gave him operational chops. That duality mattered in a market where most healthcare AI startups lean too heavily on either the clinical side or the engineering side, rarely mastering both.
The team's ambitions were, perhaps unsurprisingly, transatlantic. The seed capital was earmarked for hiring engineers and clinicians, establishing a New York presence to complement the London headquarters, and refining the product specifically for U.S. payer workflows. Because while the founders were based in the UK, the real prize—and the real dysfunction—sat squarely in the American insurance system.
From Co:Helm to Anterior, and Beyond
By early 2024, the startup had quietly shed its original name. Co:Helm became Anterior—a choice that felt more clinical, more forward-leaning. The rebrand surfaced publicly as the company began gaining traction with health insurers looking to offload some of the crushing operational burden of prior auth reviews.
The seed round, it turned out, was just the warm-up.
In June 2024, Anterior closed a $20 million Series A led by NEA, with Sequoia and other early backers doubling down. The valuation: $95 million. Not bad for a company that had barely existed a year earlier. Then came February 2026—a $40 million growth round from FPV and Kinnevik that brought total funding to $64 million and signaled something important: the market's appetite for clinical automation wasn't hypothetical anymore. It was here, and it was hungry.
The trajectory raises questions about timing. Prior authorization has been a punching bag for decades, a policy mechanism that physicians loathe and patients endure. Why now? Why this team?
Part of the answer lies in the maturation of large language models and clinical AI—tools that can actually parse medical records, insurance policies, and approval criteria with something resembling competence. Another part lies in mounting political and regulatory pressure to streamline prior auth, with the Centers for Medicare & Medicaid Services proposing new rules to accelerate turnaround times.
But perhaps the simplest explanation is that someone finally built something that worked. And in healthcare, where inertia is the default setting, that alone is worth betting on.
Anterior's story is still being written. The company hasn't disclosed revenue figures or customer names publicly, and the broader question of whether AI can truly replace human judgment in high-stakes clinical decisions remains contentious. But for Sequoia and the string of investors who followed, the $64 million wager suggests they believe Mahmoud and Mahmood are onto something.
Whether it's a trillion-dollar something remains to be seen.
